Therapure Biomanufacturing Contracted To Produce Insmed's ARIKAYCE

Therapure Biomanufacturing, a division of Therapure Biopharma, has announced it has entered into an agreement with Insmed Incorporated to manufacture the company’s ARIKAYCE treatment. Under the agreement between the two companies, Therapure will be responsible for the construction of a manufacturing site which will be used in the product’s scale-up. Therapure is also responsible for the commercial aseptic formulation and fill/finish manufacturing of ARIKAYCE.

Therapure will be manufacturing the drug at the company’s facility in Mississauga, Ontario. The company will be using technologies, such as the proprietary liposomal encapsulation process, in order to produce the final product.

 Nick Green, Therapure’s President and CEO, said that the company was excited to work with Insmed. “We are delighted to partner with Insmed to assist with the advancement of this innovative technology for serious and life-threatening pulmonary diseases.” said Green.

Insmed has long focused on developing drugs that can help the prognosis of patients with dangerous lung diseases which are oftentimes caused by infections. Insmed’s VP of Technical Operations, Dr. Peter Clarke, also released a statement. “Insmed looks forward to working with Therapure for the commercial supply of our key drug candidate ARIKAYCE. Therapure's proven cGMP manufacturing capabilities and expertise with aseptic formulation will support the planned global commercial launch of ARIKAYCE,” said Clarke.

ARIKAYCE is liposomal amikacin, which patients inhale. The drug treats rare lung infections which can cause adverse conditions in patients, such as cystic fibrosis and non-tuberculous mycobacteria. Patients with either of these diseases are considered orphan patient populations.